Though the number of patients with continuously low ALT (≦30 IU/l ) are few in this study, suppressing ALT ≦ 30 IU/l with anti-inflammatory drugs post IFN, may partly contribute in delaying HCC occurrence in patients, who are NR to initial IFN therapy. This evidence concerns the gene GPT and hepatocellular carcinoma.